0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover979.27%IV63.93%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7577Delta0.1339Gamma1.74Leverage Ratio-0.0271Theta0.0001Rho1.32Eff Leverage0.0007Vega
Adaptimmune Therapeutics Stock Discussion
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet